A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial.,Journal of Gynecologic Oncology

当前位置： X-MOL 学术 › J. Gynecol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial.
Journal of Gynecologic Oncology ( IF 3.9 ) Pub Date : 2021-6-5 , DOI: 10.3802/jgo.2021.32.e64
Kensuke Hori ₁ , Shin Nishio ₂ , Kimio Ushijima ₂ , Yuka Kasamatsu ₃ , Eiji Kondo ₄ , Kazuhiro Takehara ₅ , Kimihiko Ito ₁

Affiliation

To determine the safety and efficacy of dose-dense (dd) paclitaxel (PTX) and carboplatin (CBDCA) in treating advanced or recurrent endometrial cancer.

中文翻译：